Our Product
Submit your molecule portfolio. Omni-Search scans 357,214 drug perturbation signatures and returns a ranked shortlist of new indications for your approved drugs, each with a go/no-go dossier your team can act on.
How it works
A list of your approved or off-patent molecules. No structures, no assay data and no confidential chemistry required to start.
Each molecule is scored against every candidate indication using transcriptional reversal, selectivity and network evidence, with permutation nulls behind the scores.
A ranked shortlist with the reasoning, the counter-evidence and a clear recommendation on which candidates deserve wet-lab spend.
What is inside
A single similarity metric produces plausible-looking nonsense. Every candidate has to survive all four layers before it reaches a dossier.
164 million rows of drug-induced transcriptional change, precomputed so a portfolio can be scored in one pass rather than one molecule at a time.
Genetic perturbation data used to separate signatures that reflect real target engagement from signatures that only look similar.
Response varies by lineage. Candidates are scored against the cell lines that represent the indication, not against a pooled average.
Pathway and interaction context, so a ranked hit comes with a mechanistic argument rather than a correlation alone.
Validation
We ran Omni-Search over a 95-molecule portfolio from an Indian generics manufacturer. It covered 82 of the 95 molecules and scored 1,722 drug-cancer pairs.
As a control, we checked whether the engine could recover a repurposing result that is already established. It ranked bortezomib in multiple myeloma first. That is a sanity check on the method rather than a claim about any new candidate, and we report it as such.
What you receive
The output is a decision document, not a spreadsheet of scores. It is written so a lifecycle-management team can take it to a portfolio review unchanged.
Who it is for
Indian manufacturers supply a large share of world generic demand but have few tools for lifecycle management. A new indication supported by new clinical study can carry three years of FDA exclusivity. Omni-Search exists to find those candidates early, and to rule out the ones that are not worth the study.
Dossiers are priced for Indian lifecycle-management budgets, typically Rs 3-10 lakh depending on portfolio size and the depth of evidence review required.
The demo is public and searches the live signature set. Bring one of your own molecules.